MET Oncogene Controls Invasive Growth by Coupling with NMDA Receptor.

MET tyrosine kinase receptor glutamate receptor hepatocyte growth factor tumor invasion

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
11 Sep 2022
Historique:
received: 18 08 2022
revised: 08 09 2022
accepted: 09 09 2022
entrez: 23 9 2022
pubmed: 24 9 2022
medline: 24 9 2022
Statut: epublish

Résumé

The N-methyl-D-aspartate receptor (NMDAR) is a glutamate-gated ion channel involved in excitatory synaptic transmission. Outside the nervous system, the NMDAR is expressed in a variety of tissues and in cancers, notably in the highly invasive and metastatic triple-negative breast carcinoma. MET encodes the tyrosine kinase receptor for HGF and is a master regulator gene for "invasive growth". In silico analysis shows that high expression of the NMDAR2B subunit is a negative prognostic factor in human invasive breast carcinoma. Here, we show that in triple-negative breast cancer cell lines NMDAR2B and MET proteins are coexpressed. HGF stimulation of these cells is followed by autophosphorylation of the MET kinase and phosphorylation of the NMDAR2B subunit at tyrosines 1252 and 1474. MET and phosphorylated NMDAR2B are physically associated, as demonstrated by co-immunoprecipitation, confocal immunofluorescence, and proximity ligation assays. Notably, pharmacological inhibition of NMDAR by MK801 and ifenprodil blunts the biological response to HGF. These results demonstrate the existence of a MET-NMDAR crosstalk driving the invasive program, paving the way for a new combinatorial therapy.

Identifiants

pubmed: 36139568
pii: cancers14184408
doi: 10.3390/cancers14184408
pmc: PMC9496780
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : AIRC-5x1000
ID : 21052
Organisme : AIRC-19-IG
ID : 23820
Organisme : Italian Ministry of Health
ID : "Ricerca corrente 2022"

Références

J Neurosci Res. 2012 Sep;90(9):1743-55
pubmed: 22535512
Int J Cancer. 1997 Jun 20;74(3):301-9
pubmed: 9221809
Cell Cycle. 2006 Jul;5(14):1560-8
pubmed: 16861928
Nat Neurosci. 2000 Jul;3(7):661-9
pubmed: 10862698
Mol Cell Proteomics. 2008 Aug;7(8):1420-33
pubmed: 18426791
Mol Biol Cell. 2007 Jan;18(1):76-83
pubmed: 17065554
Pulm Circ. 2015 Dec;5(4):619-30
pubmed: 26697169
Front Cell Dev Biol. 2021 Jun 09;9:683609
pubmed: 34179015
J Physiol. 2021 Jan;599(2):431-441
pubmed: 32034761
J Neurosci Res. 2020 Nov;98(11):2115-2129
pubmed: 31746037
Int J Cancer. 2005 Feb 10;113(4):678-82
pubmed: 15455388
Clin Pharmacol. 2017 Jul 17;9:79-86
pubmed: 28761381
Nat Rev Neurosci. 2013 Jun;14(6):383-400
pubmed: 23686171
Int J Mol Sci. 2021 Dec 15;22(24):
pubmed: 34948279
Clin Pharmacol. 2010;2:31-40
pubmed: 22291485
Dev Dyn. 2012 Oct;241(10):1562-74
pubmed: 22911543
Nature. 2019 Sep;573(7775):526-531
pubmed: 31534217
Nat Rev Cancer. 2018 Jun;18(6):341-358
pubmed: 29674709
Cell Rep. 2018 Aug 7;24(6):1523-1535
pubmed: 30089263
Biol Psychiatry. 2016 Dec 15;80(12):933-942
pubmed: 27086544
Oncogene. 2006 Apr 6;25(15):2273-84
pubmed: 16288205
J Cell Biol. 1997 Jul 28;138(2):423-34
pubmed: 9230083
Synapse. 2007 Apr;61(4):199-204
pubmed: 17230549
Breast Cancer Res Treat. 2010 Jul;122(2):307-14
pubmed: 19784770
J Cell Sci. 2015 Dec 1;128(23):4317-27
pubmed: 26483385
Cell. 2013 Mar 28;153(1):86-100
pubmed: 23540692
J Neurosci. 2014 Dec 3;34(49):16166-79
pubmed: 25471559
Breast Cancer Res. 2010;12(4):208
pubmed: 20804567
J Biol Chem. 2001 Jan 5;276(1):693-9
pubmed: 11024032
Cold Spring Harb Perspect Biol. 2013 Jul 01;5(7):
pubmed: 23818496
Neuron. 2005 Sep 15;47(6):845-57
pubmed: 16157279
J Biol Chem. 2014 May 9;289(19):13476-91
pubmed: 24634221
Neuroscience. 2004;128(1):155-62
pubmed: 15450362

Auteurs

Simona Gallo (S)

Department of Oncology, University of Turin, Strada Provinciale 142, 10060 Candiolo, Italy.
Candiolo Cancer Institute, FPO-IRCCS, Strada Provinciale 142, 10060 Candiolo, Italy.

Annapia Vitacolonna (A)

Department of Oncology, University of Turin, Strada Provinciale 142, 10060 Candiolo, Italy.
Candiolo Cancer Institute, FPO-IRCCS, Strada Provinciale 142, 10060 Candiolo, Italy.

Paolo Comoglio (P)

IFOM, FIRC Institute for Molecular Oncology, Via Adamello 16, 20139 Milano, Italy.

Tiziana Crepaldi (T)

Department of Oncology, University of Turin, Strada Provinciale 142, 10060 Candiolo, Italy.
Candiolo Cancer Institute, FPO-IRCCS, Strada Provinciale 142, 10060 Candiolo, Italy.

Classifications MeSH